Retrospective evaluation of the effectiveness of the glargine U300: A single center experience

Year 2024, Volume: 17 Issue: 1, 57 - 65, 30.04.2024

Deniz Gezer , Sencer Yurtsever

Abstract

Objective: We investigated the long-term (12 and 24 months) effects of glargine U300 on fasting plasma glucose (FPG), HbA1c and the incidence of hypoglycemia in patients. Method: Patients who applied to the Internal Medicine outpatient clinic with the diagnosis of Type 2 DM between January 2017 and January 2021 and were started on glargine U300 were retrospectively analyzed. Results: Gla-300 treatment significantly improved mean blood glucose levels at both 12 and 24 months (tabtotcomp.). At the beginning of the treatment, the mean blood glucose level was 252.19±92.55 mg/dl. However, it was 203.08±82.09 mg/dl at the 12th month and 200.27±73.78 on the 24th month. Similarly, with Gla-300 treatment, the percentage of HbA1c was found to be significantly lower at both 12 and 24 months. The mean initial HbA1c was 9.9±1.925%, this value was found to be 8.66±1.969 at the 12th month and 8.51±1.43 at the 24th month. Conclusion: Glargine U300 is a long-acting basal insulin that both reduces the risk of hypoglycemia and provides targeted glycemic control, as supported by our study findings.

Keywords

Glargine U300, Hypoglycemia, Glycemic control, Long-acting basal insulin

Project Number

yoktur

Glargin U300'ün etkinliğinin geriye yönelik olarak değerlendirilmesi: Tek merkez deneyimi

Abstract

Amaç: Glargin U300'ün açlık kan şekeri (AKŞ) ve HbA1c üzerindeki uzun vadeli (12 ve 24 ay) etkilerini ve tedavi sırasında hipoglisemi gelişme sıklığını araştırmayı amaçladık. Yöntem: Ocak 2017-Ocak 2021 tarihleri arasında Dahiliye polikliniğine Tip 2 DM tanısı ile başvuran ve glargin U300 tedavisi başlanan 96 hasta retrospektif olarak incelendi. Bulgular: Tedavi başlangıcında ortalama kan glukoz düzeyi 252.19±92.55 mg/dl iken 12. ayda 203.08±82.09 mg/dl, 24. ayda 200.27±73.78 mg/dl ye kadar düşme saptandı. Benzer şekilde glargin U300 tedavisi ile HbA1c yüzdesinin hem 12 hem de 24. ayda anlamlı derecede düştüğü bulundu. Ortalama başlangıç HbA1c %9.9±1.925 iken 12. ayda 8.66±1.969 ve 24. ayda 8.51±1.430 idi. Glargin U- 300 tedavisi alan 96 hastanın altısında (%6.3) acil serviste hipoglisemi atağı geliştiği saptandı. Sonuç: Glargin U300, çalışma bulgularımızla da desteklendiği üzere hem hipoglisemi riskini azaltmada hem de hedefe yönelik glisemik kontrolü sağlamada etkin bir bazal insülindir.

Keywords

Glargine U300, hipoglisemi, glisemik kontrol, uzun etkili bazal insülin

Supporting Institution

yoktur

Project Number

yoktur

References

• International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels; 2019. http://www.diabetesatlas.org; https://www.idf.org/ aboutdiabetes/complications.html 01.04.2023 tarihinde erişilmiştir.
• Garber AJ, Handelsman Y, Grunberger G,et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrıne Practıce, 2020;26(1):107-139. doi:10.4158/CS-2019-0472
• Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92–101. doi:10.1111/dme.12261
• Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94(3):352–63. doi:10.1016/j.diabres.2011.10.021
• Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012;28(12):1947–58. doi:10.1185/03007995.2012.743457
• Rosenzweig JL, Conlin PR, J Gonzalvo JD, et al. 2019 Endocrine Society Measures Set for Older Adults With Type 2 Diabetes Who Are at Risk for Hypoglycemia. J Clin Endocrinol Metab, 2020;105(4):969-990. doi: 10.1210/clinem/dgz250. doi:10.1210/clinem/dgz250
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79. doi:10.2337/dc12-0413
• Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104–19. doi:10.1002/dmrr.2469
• Maiorino MI, Petrizzo M, Capuano A, et al. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes? Expert Opin Biol Ther. 2014;14(6):799–808. doi:10.1517/14712598.2014.895812
• Woo VC. New insulins and new aspects in insulin delivery. Can J Diabetes. 2015;39(4):335–43. doi:10.1016/j.jcjd.2015.04.006
• Kişioğlu SV, Demir AS, Tufekci D, et al. Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience. Arch Med Sci Atheroscler Dis. 2021;6:e102-e108. Published 2021 Apr 20. doi:10.5114/amsad.2021.105562
• Haliloglu O, Korkmaz M, Korkmaz OP, Sahin S, Durcan E, Siva ZO. Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience. Ann Med Res, 2020;27(7):1961-1965. DOI: 10.5455/annalsmedres.2020.04.363
• Wolnik B, Hryniewiecki A, Pisarczyk-Wiza D,. Szczepanik T, Klupa T. Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study. Diabetes Ther 2022;13:301–310. https://doi.org/10.1007/s13300-021-01199-4
• Yki-Jarvinen H, Bergenstal R, Ziemen M, et al on behalf of the EDITION 2 Study Investigators. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care, 2014;37:3235-3243. | DOI: 10.2337/dc14-0990.
• Duque N, Artime E, Romera I, et al. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Advances in Therapy [Internet]. 2021 May 29;38(7):3857–71. Available from: https://doi.org/10.1007/s12325-021-01773-z
• Van Mark G, Lanzinger S, Sziegoleit S, et al. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries. Advances in Therapy [Internet]. 2019 May 22;36(7):1628–41. Available from: https://doi.org/10.1007/s12325-019-00983-w
• Tibaldi J, Hadley‐Brown M, Liebl A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism [Internet]. 2019 Apr;21(4):1001–9. Available from: https://doi.org/10.1111/dom.13616
• Zick R, Petersen B, Richter M, Haug C, SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 2007; 9:483–92. doi: 10.1089/dia.2007.0230
• Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in Type 2 Diabetes--More Common Than You Think: A Continuous Glucose Monitoring Study. J Diabetes Sci Technol 2015; 9:999–1005. doi: 10.1177/1932296815581052
• Heller SR, Peyrot M, Oates SK, Taylor AD. Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen. BMJ Open Diab Res Care, 2020;8:e001194. doi:10.1136/bmjdrc-2020-001194
• Philis-Tsimikas A, Klonoff DC, Khunti K, Baj, et al; CONCLUDE Study Group. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia, 2020;63(4):698-710. doi: 10.1007/s00125-019-05080-9.
• Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic Medicine, 2003;20(12):1016–21.doi: 10.1046/j.1464-5491.2003.01072.x
• Akram K, Pedersen B U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabetic Medicine. 2006;23(7):750–6. doi: 10.1111/j.1464-5491.2006.01880.x.